Turn Bio Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies

LongeVC portfolio company Turn Biotechnologies has announced a global licensing agreement with HanAll Biopharma to develop medicines for age-related eye and ear conditions. The deal is valued at over $300 million. The collaboration will utilize Turn Bio's Epigenetic Reprogramming of Age (ERA™) technology and eTurna™ delivery platform to target age-related diseases. The partnership expands Turn Bio's development focus and enables the company to accelerate the development of transformative therapies for eye and ear indications with the potential to benefit patients worldwide.

You can read the full announcement here and coverage of the story in Longevity.Technology here.